Kolon Group entered the FDA Phase 3 clinical trial with the arthritis treatment ‘Invossa’ in the U.S.

The world’s first degenerative arthritis gene treatment ‘Invossa™,’ developed by Kolon Group (President : Woong-yeol Lee), will get on a Phase 3 clinical trial for FDA in the U.S. This is the first case to enter a Phase 3 clinical trial in the states as a degenerative arthritis gene treatment.

Invossa, the official brand name for the new drug, which has been known as ‘TissueGene-C’ (developmen...